X4 Pharmaceuticals

Intensifying Trial Risks Will Hobble Returns Yet Open Global Potential

AnalystLowTarget

Not Invested

Community Contributor

Published

01 Jun 25

AnalystLowTarget's Fair Value

US$3.50

4.3% undervalued

03 Sep

US$3.35

-83.3%

-0.9%

-83.3%

-0.9%

You can edit this narrative until Jun 1 10:20 PM. Then, changes will post as Updates.

Author's Valuation

US$3.54.3% undervalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$3.5

4.3% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

33.34%

Biotech revenue growth rate

8.48%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.40%

Calculation

US$3.87m

Earnings '28

28.71x

PE Ratio '28

US$111.24m

Market Cap '28

US$111.24m

Market Cap '28

25.06m

No. shares '28

US$4.44

Share Price '28

US$4.44 Share Price '28

Discounted to 2025 @ 8.23% p.a.

US$3.50

Fair Value '25